Diabetes · Ocala, FL
Diabetes studies in Ocala, FL
6 recruiting studies have a site in Ocala.
6 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Ocala, FL + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Ocala, FL + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Ocala, FL + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Ocala, FL + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and…
Novo Nordisk A/S
- Location
- Ocala, FL + 55 other US sites
- Eligibility basics
- Ages 45+
- RecruitingPhase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Eli Lilly and Company
- Location
- Ocala, FL + 35 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Studies commonly set an HbA1c range, a diagnosis duration and a list of allowed or excluded medications. Some also recruit people without diabetes as a comparison group.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.